Strubel, Alexander http://orcid.org/0000-0002-8175-962X
Münick, Philipp http://orcid.org/0000-0002-0548-0897
Hartmann, Oliver http://orcid.org/0000-0002-5663-645X
Chaikuad, Apirat
Dreier, Birgit
Schaefer, Jonas V.
Gebel, Jakob
Osterburg, Christian http://orcid.org/0000-0002-2144-583X
Tuppi, Marcel
Schäfer, Birgit
Buck, Viktoria
Rosenfeldt, Mathias
Knapp, Stefan http://orcid.org/0000-0001-5995-6494
Plückthun, Andreas http://orcid.org/0000-0003-4191-5306
Diefenbacher, Markus E. http://orcid.org/0000-0002-7402-7949
Dötsch, Volker http://orcid.org/0000-0001-5720-212X
Funding for this research was provided by:
Deutsche Krebshilfe (70112491, 70114554)
Article History
Received: 30 August 2023
Revised: 15 September 2023
Accepted: 3 October 2023
First Online: 12 October 2023
Competing interests
: Andreas Plückthun is a cofounder and shareholder of Molecular Partners AG, who are commercializing the DARPin technology. All other authors declare that they have no competing interests.
: All in vivo experiments were approved by the Regierung Unterfranken and the ethics committee under the license numbers 2532-2-362, 2532-2-367 and 2532-2-374. Human lung cancer samples were obtained from the Pathology Department of the University Hospital Würzburg (Germany) with informed consent from all patients. Experiments are in agreement with the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. Samples were approved under Ethics Approval 17/01/2006 (University Hospital Würzburg).